Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $356034.0.

  • China Pharma Holdings' Depreciation & Amortization (CF) fell 4891.49% to $356034.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 4925.44%. This contributed to the annual value of $2.6 million for FY2024, which is 492.39% down from last year.
  • As of Q3 2025, China Pharma Holdings' Depreciation & Amortization (CF) stood at $356034.0, which was down 4891.49% from $320863.0 recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Depreciation & Amortization (CF) peaked at $976457.0 during Q3 2021, and registered a low of $320863.0 during Q2 2025.
  • Over the past 5 years, China Pharma Holdings' median Depreciation & Amortization (CF) value was $694842.0 (recorded in 2023), while the average stood at $640330.6.
  • As far as peak fluctuations go, China Pharma Holdings' Depreciation & Amortization (CF) skyrocketed by 4502.71% in 2021, and later tumbled by 5659.63% in 2025.
  • China Pharma Holdings' Depreciation & Amortization (CF) (Quarter) stood at $710716.0 in 2021, then fell by 10.03% to $639425.0 in 2022, then rose by 8.82% to $695835.0 in 2023, then crashed by 35.61% to $448073.0 in 2024, then fell by 20.54% to $356034.0 in 2025.
  • Its Depreciation & Amortization (CF) was $356034.0 in Q3 2025, compared to $320863.0 in Q2 2025 and $329313.0 in Q1 2025.